NOVO.B.DK

247.15

-2.72%↓

GMAB.DK

1,764

-0.28%↓

HLUNB.DK

38.08

-1.19%↓

ZEAL.DK

261.2

-2.72%↓

AMBUB.DK

74.2

-2.56%↓

NOVO.B.DK

247.15

-2.72%↓

GMAB.DK

1,764

-0.28%↓

HLUNB.DK

38.08

-1.19%↓

ZEAL.DK

261.2

-2.72%↓

AMBUB.DK

74.2

-2.56%↓

NOVO.B.DK

247.15

-2.72%↓

GMAB.DK

1,764

-0.28%↓

HLUNB.DK

38.08

-1.19%↓

ZEAL.DK

261.2

-2.72%↓

AMBUB.DK

74.2

-2.56%↓

NOVO.B.DK

247.15

-2.72%↓

GMAB.DK

1,764

-0.28%↓

HLUNB.DK

38.08

-1.19%↓

ZEAL.DK

261.2

-2.72%↓

AMBUB.DK

74.2

-2.56%↓

NOVO.B.DK

247.15

-2.72%↓

GMAB.DK

1,764

-0.28%↓

HLUNB.DK

38.08

-1.19%↓

ZEAL.DK

261.2

-2.72%↓

AMBUB.DK

74.2

-2.56%↓

Search

Coloplast A-S (Class B)

Deschisă

444.1 -3.08

Rezumat

Modificarea prețului

24h

Curent

Minim

446

Maxim

460.5

Indicatori cheie

By Trading Economics

Venit

522M

1.4B

Vânzări

83M

7B

P/E

Medie Sector

25.385

61.417

EPS

6.32

Randament dividend

4.98

Marjă de profit

19.835

Angajați

16,983

EBITDA

309M

2.3B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+11.86% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.98%

2.40%

Următoarele câștiguri

12 mai 2026

Data viitoare de dividende

20 mai 2026

Următoarea dată ex-dividende

18 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-17B

101B

Deschiderea anterioară

447.18

Închiderea anterioară

444.1

Coloplast A-S (Class B) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

10 mar. 2026, 20:38 UTC

Câștiguri

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

10 mar. 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

10 mar. 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

10 mar. 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

10 mar. 2026, 23:37 UTC

Achiziții, Fuziuni, Preluări

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

10 mar. 2026, 23:35 UTC

Market Talk
Evenimente importante

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

10 mar. 2026, 23:06 UTC

Câștiguri

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

10 mar. 2026, 22:51 UTC

Evenimente importante

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

10 mar. 2026, 21:39 UTC

Achiziții, Fuziuni, Preluări

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

10 mar. 2026, 21:21 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

10 mar. 2026, 21:15 UTC

Câștiguri

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

10 mar. 2026, 21:15 UTC

Achiziții, Fuziuni, Preluări

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

10 mar. 2026, 21:14 UTC

Câștiguri

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

10 mar. 2026, 21:13 UTC

Câștiguri

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

10 mar. 2026, 21:12 UTC

Câștiguri

Franco-Nevada 4Q Rev $597.3M >FNV

10 mar. 2026, 21:12 UTC

Câștiguri

Franco-Nevada 4Q EPS $1.90

10 mar. 2026, 20:57 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar. 2026, 20:50 UTC

Market Talk
Câștiguri

Tech, Media & Telecom Roundup: Market Talk

10 mar. 2026, 20:44 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar. 2026, 20:34 UTC

Market Talk
Câștiguri

Global Equities Roundup: Market Talk

10 mar. 2026, 20:34 UTC

Market Talk
Câștiguri

Oracle Building More Software for Less Money After Restructuring -- Market Talk

10 mar. 2026, 20:23 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

10 mar. 2026, 20:16 UTC

Câștiguri

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

10 mar. 2026, 20:14 UTC

Câștiguri

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

10 mar. 2026, 20:14 UTC

Câștiguri

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

10 mar. 2026, 20:13 UTC

Câștiguri

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

10 mar. 2026, 20:12 UTC

Câștiguri

Oracle Stock Jumps on Earnings Beat -- Barrons.com

Comparație

Modificare preț

Coloplast A-S (Class B) Așteptări

Obiectiv de preț

By TipRanks

11.86% sus

Prognoză pe 12 luni

Medie 901.38 DKK  11.86%

Maxim 1,056 DKK

Minim 720 DKK

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruColoplast A-S (Class B) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

8 ratings

2

Cumpărare

4

Păstrare

2

Vânzare

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat